US 11,890,265 B2
Cancer starvation therapy
Pedro Anastacio Serrano-Ojeda, San Juan, PR (US)
Assigned to SERBIG PHARMACEUTICALS CORPORATION, Bayamon, PR (US)
Filed by SERBIG PHARMACEUTICALS CORP., Bayamon, PR (US)
Filed on Mar. 25, 2019, as Appl. No. 16/363,758.
Application 16/363,758 is a division of application No. 14/860,204, filed on Sep. 21, 2015, granted, now 10,292,956.
Application 14/860,204 is a continuation in part of application No. 12/552,116, filed on Sep. 1, 2009, abandoned.
Prior Publication US 2019/0216758 A1, Jul. 18, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/07 (2006.01); A61K 31/14 (2006.01); A61K 31/19 (2006.01); A61K 31/51 (2006.01); A61K 33/06 (2006.01); A61K 33/18 (2006.01); A61K 36/28 (2006.01); A61K 39/00 (2006.01); A61K 31/122 (2006.01); A61K 31/194 (2006.01); A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/55 (2006.01); A61K 31/198 (2006.01); A61K 31/28 (2006.01); A61N 5/10 (2006.01); A61N 5/02 (2006.01); A61K 41/00 (2020.01); C07F 1/00 (2006.01); A61K 47/54 (2017.01); A61K 31/197 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/455 (2006.01); A61K 31/519 (2006.01); A61K 31/525 (2006.01); A61K 31/555 (2006.01); A61K 31/593 (2006.01); A61K 31/714 (2006.01); A61K 31/4415 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 31/28 (2013.01); A61K 41/0038 (2013.01); A61K 47/542 (2017.08); A61N 5/02 (2013.01); A61N 5/10 (2013.01); C07F 1/00 (2013.01); A61N 2005/109 (2013.01); A61N 2005/1087 (2013.01)] 1 Claim
 
1. A radiosensitizing containing glutamine-ligand-high Z element compound for treating tumorigenic cells in combination with a high energy radiation, wherein the glutamine-ligand-high Z element compound is a compound of the Formula:

OG Complex Work Unit Chemistry